Why Azenta Stock Crushed it on Wednesday
Its final earnings report for fiscal 2026 was impressive.
On Wednesday, investors rushed to buy shares of Azenta's (AZTA +20.80%) healthcare tech stock, driving it up by nearly 21%. This outperformed the broader market, which saw the S&P 500 gain only 1.3%. Azenta specializes in automated sample storage for the healthcare industry. In its fiscal fourth quarter of 2026, the company reported revenue growth of 5% year over year to $167 million, with its sample management solutions unit increasing by 9% to $94 million.
The company's multiomics unit, which analyzes multiple types of molecules, remained flat at $73 million. Azenta's net income, on a non-GAAP basis, was $12.3 million, or $0.28 per share, an improvement from $9.6 million in the same period last year. Analysts had projected lower revenue and profit, highlighting Azenta's unexpected performance.
For the full fiscal year, the company anticipates revenue between $648 million and $660 million, with adjusted EBITDA margin expanding by 200 to 250 basis points from the 2026 result.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
